Claims for Patent: 9,114,068
✉ Email this page to a colleague
Summary for Patent: 9,114,068
Title: | Treating patients with intravenous ibuprofen |
Abstract: | Methods of treating a patient in need thereof, comprising administering to the critically ill patient an intravenous pharmaceutical composition comprising ibuprofen in an amount effective to treat at least one condition in the patient chosen from pain, inflammation, and fever and to provide a clinically relevant effect on mean arterial pressure of the patients during the dosage interval comprising no increase or no statistically significant increase in mean arterial pressure. |
Inventor(s): | Pavliv; Leo (Cary, NC), Rock; Amy Dix (Thompson Station, TN) |
Assignee: | Cumberland Pharmaceuticals, Inc. (Nashville, TN) |
Application Number: | 14/264,267 |
Patent Claims: |
1. A method of treating pain in human patients in need thereof, comprising administering to the human patients an intravenous ibuprofen pharmaceutical composition in an effective dose
from about 400 mg to about 800 mg about every 4 to about 6 hours to treat pain, wherein the patients suffer from high blood pressure and do not suffer from inflammation, such that the mean arterial pressure of the patients does not increase during the
dosage.
2. The method of claim 1, wherein the patients are critically ill, and the dose of ibuprofen administered attains a mean Cmax of about 20.8 .mu.g/ml to about 75 .mu.g/ml. 3. The method of claim 2, wherein the administered intravenous ibuprofen pharmaceutical composition attains a mean AUC of about 36.8 .mu.gh/ml to about 117.5 .mu.gh/ml. 4. The method of claim 1, wherein the ibuprofen pharmaceutical composition is an aqueous solution of arginine and ibuprofen. 5. The method of claim 4, wherein the molar ratio of arginine to ibuprofen is selected from less than or equal to 1:1, less than or equal to 0.99:1, less than or equal to 0.98:1, less than or equal to 0.97:1, less than or equal to 0.96:1, less than or equal to 0.95:1, less than or equal to 0.94:1, less than or equal to 0.93:1, less than or equal to 0.92:1, less than or equal to 0.91:1, less than or equal to 0.90:1, less than or equal to 0.60:1. 6. The method of claim 1, comprising administering the dose of ibuprofen to the patients about every 6 hours. 7. The method of claim 2, wherein the critically ill patients are patients receiving a treatment selected from the group consisting of vasopressor support, mechanical ventilation, dialysis, multiple antibiotics, pulmonary artery catheter or arterial blood pressure catheter, and combinations of any of the foregoing. 8. The method of claim 1, wherein the dose of ibuprofen pharmaceutical composition administered is selected from the group consisting of 400 mg, 450 mg, 500 mg, 550 mg, 600 mg, 650 mg, 700 mg, and 800 mg. 9. The method of claim 1, wherein the dose of the ibuprofen pharmaceutical composition is administered over 30 minutes. 10. The method of claim 1, wherein the dose of the ibuprofen pharmaceutical composition is about 800 mg. 11. The method of claim 1, wherein the dose of the ibuprofen pharmaceutical composition is about 400 mg. 12. The method of claim 2, wherein the critically ill patients are patients being treated in an Intensive Care Unit. 13. The method of claim 2, wherein the critically ill patients are being administered packed red blood cells. 14. The method of claim 1, comprising administering the dose of the ibuprofen pharmaceutical composition to the patients about every 4 hours. |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.